World Health Organization site
Skip Navigation Links

Please fill this short user satisfaction survey


Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 12 December 2020
Main ID:  NCT03204929
Date of registration: 28/06/2017
Prospective Registration: Yes
Primary sponsor: Collaborative Medicinal Development Pty Limited
Public title: Dose Escalation Study of Cu(II)ATSM in Parkinson's Disease
Scientific title: A Phase 1 Dose Escalation Study of Cu(II)ATSM Administered Orally to Patients With Early Idiopathic Parkinson's Disease
Date of first enrolment: August 14, 2017
Target sample size: 31
Recruitment status: Completed
URL:  https://clinicaltrials.gov/show/NCT03204929
Study type:  Interventional
Study design:  Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).  
Phase:  Phase 1
Countries of recruitment
Australia
Contacts
Name:     Andrew Evans, MD
Address: 
Telephone:
Email:
Affiliation:  Melbourne Health
Key inclusion & exclusion criteria

Inclusion Criteria:

- Signed informed consent prior to initiation of any study-specific procedures

- Early idiopathic Parkinson's disease (PD) with at least two of the cardinal signs of
PD (resting tremor, bradykinesia, rigidity, postural instability). If tremor is not
present, must have unilateral onset and persistent asymmetry of symptoms.

- Hoehn & Yahr stage = 2

- First PD motor symptoms occurred = 5 years prior to screening visit

- Use of dopaminergic therapy allowed provided dose is stable for at least 8 weeks prior
to screening visit

- Use of amantadine and/or anticholinergics allowed provided dose is stable for at least
8 weeks prior to screening visit

- Use of CNS-acting medications allowed provided dose is stable for at least 4 weeks
prior to screening visit

- Age = 30 years at time of PD diagnosis

- Adequate bone marrow reserve, liver and renal function:

Absolute neutrophil count = 1500/µL; Platelet count = 150,000/µL; Hemoglobin = 11 g/dL;
Creatinine clearance = 6- mL/min (Cockroft & Gault formula); ALT and/or AST = 2 x ULN;
total bilirubin = 1.5 x ULN; albumin = 2.8 g/dL

- Women and men with partners of childbearing potential must take effective
contraception while on study and women of childbearing potential must have a negative
pregnancy test and be non-lactating at screening

Exclusion Criteria:

- Atypical Parkinsonism

- Taking = 3 dopaminergic medications

- Exposure to typical or atypical antipsychotics or other dopamine blocking agents
within 6 months prior to screening visit

- Exposure to any other investigational agent within 6 months or 2 investigational
agents within 12 months prior to screening visit

- Known immune compromising illness or treatment

- History of brain surgery for PD, including deep brain stimulation and stem cell
transplants

- History of cognitive or neuropsychiatric conditions

- Inability to swallow oral medications or presence of a GI disorder (eg, malabsorption)
deemed to jeopardize intestinal absorption of study drug

- Active GI disease (excluding GERD) within 30 days prior to screening visit

- Presence of any of the following clinical conditions:

any significant non-PD CNS disorder; drug abuse or alcoholism; unstable cardiac, pulmonary,
renal, hepatic, endocrine or hematologic disease; active infectious disease; AIDS or
AIDS-related complex; malignancy within 3 years of screening (other than fully excised
non-melanoma skin cancer, cured in situ cervical carcinoma, early stage bladder cancer, or
DCIS of breast); psychosis or untreated major depression within 30 days of screening;
dementia

- Current use of strong inducers or inhibitors of CYPs 2C19 and 2D6



Age minimum: 30 Years
Age maximum: N/A
Gender: All
Health Condition(s) or Problem(s) studied
Parkinson Disease
Intervention(s)
Drug: Cu(II)ATSM
Primary Outcome(s)
Recommended phase 2 dose [Time Frame: 6 months]
Secondary Outcome(s)
Treatment-related changes in quality of life [Time Frame: 6 months]
Treatment-related changes in cognitive function [Time Frame: 6 months]
Treatment-related changes in disease severity [Time Frame: 6 months]
Treatment-related changes in motor function [Time Frame: 6 months]
Treatment-related changes in constipation [Time Frame: 6 months]
Secondary ID(s)
CMD-2016-002
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history Please fill this short user satisfaction survey